Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.010
+0.010 (1.00%)
Sep 3, 2026, 4:00 PM EDT - Market closed
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
9
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,133,553
Market Cap
4.02M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 9 | 0 | - | 8 | 1 |
| Dec 31, 2024 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2023 | 10 | 4 | 66.67% | 9 | 1 |
| Dec 31, 2022 | 6 | - | - | 6 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 47 |
| PMGC Holdings | 34 |
| Calidi Biotherapeutics | 29 |
| GeoVax Labs | 19 |
| VivoSim Labs | 15 |
| Mustang Bio | 4 |
| GRI Bio | 4 |
| Silo Pharma | 3 |
REVB News
- 15 days ago - Revelation Biosciences selects Avance Clinical as CRO for Phase 2/3 Titan Study - TheFly
- 15 days ago - Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study - Business Wire
- 4 weeks ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 - Accesswire
- 4 weeks ago - Revelation Biosciences Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Revelation Biosciences Earnings release: Q2 2026 - Filings
- 4 weeks ago - Revelation Biosciences announces results from market assessment for Gemini - TheFly
- 4 weeks ago - Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury - Accesswire
- 6 weeks ago - Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Accesswire